Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Orpheris enrols first patients in phase 2 clinical study evaluating OP-101 for severe Covid-19

pharmaceutical-business-reviewSeptember 03, 2020

Tag: Orpheris , COVID-19 , OP-101

PharmaSources Customer Service